Table 5 Demographic characteristics of the subjects from the WebMD data.

From: Assessment of adverse events related to anti-influenza neuraminidase inhibitors using the FDA adverse event reporting system and online patient reviews

Characteristics

Values

Number of subjects, n

440

Age, years

        Less than 19 years old, n (%)

74 (16.82)

        19 to 64 years old, n (%)

318 (72.27)

        More than 64 years old, n (%) elderly

25 (5.68)

        Unknown, n (%)

23 (5.23)

Gender (n males, %)

        Male, n (%)

110 (25.00)

        Female, n (%)

269 (61.14)

        Unknown, n (%)

61 (13.86)

Medicines

        Oseltamivir

418 (95.00)

        Zanamivir

21 (4.77)

        Peramivir

1 (0.23)

Themea

724

        Why to take the drug

270 (35.52)

        Effectiveness after taking

118 (15.53)

        Adverse events

288 (37.89)

        Price

48 (6.32)

  1. aTotal number of themes counted in each review. This is greater than the total number of reviewers because some reviews had more than one theme tied for the concern.
Back to article page